Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) vaccine unit, Fosun Adgenvax, has submitted an application for a Hong Kong listing, according to a Friday Hong Kong bourse filing.
The company plans to issue H-shares representing no more than 25% of its enlarged share capital, with an overallotment option of up to 15% of the initial offering size.
Fosun Pharma said Fosun Adgenvax is expected to remain a subsidiary after the listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments